Van de Velde M, Carvalho B
Department of Cardiovascular Sciences, Katholieke Universiteit Leuven and Department of Anaesthesiology, University Hospitals Gasthuisberg, Leuven, Belgium.
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, CA, USA.
Int J Obstet Anesth. 2016 Feb;25:66-74. doi: 10.1016/j.ijoa.2015.12.004. Epub 2015 Dec 21.
This manuscript reviews the available literature on remifentanil patient-controlled intravenous analgesia in labor focusing on efficacy and safety. Remifentanil compares favorably to other potent systemic opioids but with fewer opioid-related neonatal effects. However, remifentanil provides modest and short-lasting labor analgesia that is consistently inferior when compared to neuraxial analgesia. The initial analgesic effect provided with remifentanil also diminishes as labor progresses. In several studies, remifentanil induced significant respiratory depressant effects in laboring women with episodes of desaturation, hypoventilation and even apnea. Given the safety concerns, we recommend that remifentanil patient-controlled intravenous analgesia should not be a routine analgesia technique during labor. In cases where neuraxial analgesia is refused or contraindicated and the use of remifentanil justified, continuous and careful monitoring is required to detect respiratory depression to provide safe care of both the pregnant woman and unborn child.
本手稿回顾了关于瑞芬太尼自控静脉镇痛用于分娩的现有文献,重点关注其有效性和安全性。与其他强效全身性阿片类药物相比,瑞芬太尼具有优势,但与阿片类药物相关的新生儿效应较少。然而,瑞芬太尼提供的分娩镇痛效果中等且持续时间短,与椎管内镇痛相比始终较差。随着产程进展,瑞芬太尼最初提供的镇痛效果也会减弱。在多项研究中,瑞芬太尼在分娩妇女中引起了显著的呼吸抑制作用,出现了血氧饱和度降低、通气不足甚至呼吸暂停的情况。鉴于安全问题,我们建议瑞芬太尼自控静脉镇痛不应作为分娩期间的常规镇痛技术。在拒绝或禁忌椎管内镇痛且使用瑞芬太尼合理的情况下,需要持续且仔细的监测以检测呼吸抑制,从而为孕妇和未出生的胎儿提供安全护理。